Price complaints likely to be upheld in Greece
This article was originally published in SRA
Executive Summary
Company objections to drug pricing levels given out by the Greek government in the September price bulletin are likely to be accepted, a senior Greek government official in the department in charge of drug reimbursement has told Regulatory Affairs Pharma's sister publication Scrip. At the same time, there have been new promises that the government – which has brought in a large number of austerity measures to deal with its global debt – will pay off its debt to pharmaceutical companies, which sits around €3 billion.